DSM and Novozymes announce the launch of RONOZYME® ProAct, the first pure protease for the poultry industry. It meets the requirements of modern broiler feeding and reduces feed costs by maximizing protein utilization and improving nutritional value while enhancing animal performance. With the product DSM and Novozymes confirm their leadership through innovation in the field of feed enzymes.

RONOZYME® ProAct unlocks the nutritional value of a large variety of feed proteins by complementing the activity of digestive enzymes, such as pepsin and pancreatic proteases.

Due to increasing cost of raw materials the poultry industry is under high pressure these days. Higher feeding costs reduce profit and place stress on the entire industry. This new feed enzyme gives a way to actively minimize these rising feed costs.

RONOZYME® ProAct is launched first in Brazil, registration processes have been initiated globally. RONOZYME® ProAct is the newest feed enzyme in the great range of RONOZYME® enzymes and is fully compatible with phytases and other feed enzymes commonly used.

The overall RONOZYME® product range of feed enzymes is developed within the Alliance of DSM Nutritional Products and Novozymes and represents the most complete feed enzyme portfolio within the feed industry. “The vision of the Alliance is to provide innovative enzymes to the feed industry by joining the strengths of the two companies. RONOZYME® ProAct is a perfect outcome of this vision.” says Peter Christensen, Alliance manager at Novozymes. “Novozymes and DSM colleagues from all over the world have been part of this development and together we have created a truly innovative solution to the feed industry.” stated Christos Antipatis, Alliance manager at DSM Nutritional Products.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, the company creates tomorrow’s industrial biosolutions, improving its customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s everchanging marketplace. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Its neverending exploration of nature’s potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces. More than 4,500 employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen (NZYMB). Read more at www.novozymes.com

About DSM Nutritional Products
DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of over EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. For further company information please visit www.dsmnutritionalproducts.com.

DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.

For more information:
DSM Nutritional Products
Emma Peyrachon
Tel. +41 (0) 61 815 83 54
E-mail: emma.peyrachon@dsm.com

Novozymes
Kirsten Laugesen
Phone (direct): +45 4446 1099
Phone (cell phone): +45 3077 1099

Forward-looking statements
This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release. The English language version of the press release is leading.